GENETIC ANALYSIS NK -60 (F:8V8) — Market Cap & Net Worth
Market Cap & Net Worth: GENETIC ANALYSIS NK -60 (8V8)
GENETIC ANALYSIS NK -60 (F:8V8) has a market capitalization of $3.92 Million (€3.36 Million) as of May 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #28802 globally and #2506 in its home market, demonstrating a 90.36% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENETIC ANALYSIS NK -60's stock price €0.08 by its total outstanding shares 69087041 (69.09 Million).
GENETIC ANALYSIS NK -60 Market Cap History: 2021 to 2026
GENETIC ANALYSIS NK -60's market capitalization history from 2021 to 2026. Data shows change from $48.70 Million to $6.06 Million (-42.00% CAGR).
GENETIC ANALYSIS NK -60 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENETIC ANALYSIS NK -60's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8V8 by Market Capitalization
Companies near GENETIC ANALYSIS NK -60 in the global market cap rankings as of May 2, 2026.
Key companies related to GENETIC ANALYSIS NK -60 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
GENETIC ANALYSIS NK -60 Historical Marketcap From 2021 to 2026
Between 2021 and today, GENETIC ANALYSIS NK -60's market cap moved from $48.70 Million to $ 6.06 Million, with a yearly change of -42.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €6.06 Million | +76.47% |
| 2025 | €3.43 Million | +88.05% |
| 2024 | €1.83 Million | -57.99% |
| 2023 | €4.35 Million | -67.51% |
| 2022 | €13.38 Million | -72.54% |
| 2021 | €48.70 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of GENETIC ANALYSIS NK -60 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.92 Million USD |
| MoneyControl | $3.92 Million USD |
| MarketWatch | $3.92 Million USD |
| marketcap.company | $3.92 Million USD |
| Reuters | $3.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discove… Read more